THE FIBRINOLYTIC properties of trypsin have been known for some time. Recently, Innerfield and his associates1 reported that under certain conditions of administration and dosage the enzyme could be given intravenously to animals and to patients without untoward effects. These workers stated that the intravenous administration of trypsin caused the dissolution of thrombi and also caused a remarkable subsidence of a variety of acute inflammatory conditions. For many years investigators interested in the the thrombosis problem have sought a nontoxic in vivo thrombolytic agent. Therefore the claims of Innerfield's group warrant serious investigation.
We wish to report our clinical experiences with 30 cases of acute and chronic peripheral thrombotic disease and to summarize some preliminary data from our animal studies.
—Innerfield and his group recommended a dose of 100,000 to 250,000 units of crystalline trypsin2 diluted in 250 cc. of saline once or twice a
LAUFMAN H, ROACH HD. INTRAVENOUS TRYPSIN IN THE TREATMENT OF THROMBOTIC PHENOMENA. AMA Arch Surg. 1953;66(4):552-561. doi:10.1001/archsurg.1953.01260030567024